US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
Por Xinmei Shen — South China Morning Post – News feed
Advertisement Biomedicine: Companies Business China Business US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial
2 -MIN READ 2 -MIN 2 Listen
Xinmei Shen Published: 12:20pm, 7 Oct 2026 Updated: 12:57pm, 7 Oct 2026 US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial.
Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small cell lung cancer (NSCLC), targeting a mutation known as an epidermal growth factor receptor exon 20 insertion.
Select Voice Select Speed 0.8x 0.9x 1.0x 1.1x 1.2x 1.5x 1.75x 00:00 00:00 1x AI-generated voice
